Zura Bio (ZURA) and Its Peers Critical Contrast

Zura Bio (NASDAQ:ZURA) is one of 300 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Zura Bio to similar companies based on the strength of its valuation, profitability, institutional ownership, analyst recommendations, earnings, risk and dividends.

Valuation and Earnings

This table compares Zura Bio and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zura Bio	N/A	-$69.24 million	-2.11
Zura Bio Competitors	$575.27 million	-$70.96 million	0.18

Zura Bio’s rivals have higher revenue, but lower earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Zura Bio has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Comparatively, Zura Bio’s rivals have a beta of -4.48, suggesting that their average share price is 548% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Zura Bio and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	0	0	7	1	3.13
Zura Bio Competitors	1948	5415	14003	300	2.58

Zura Bio presently has a consensus target price of $14.67, indicating a potential upside of 1,209.52%. As a group, “Biological products, except diagnostic” companies have a potential upside of 111.82%. Given Zura Bio’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Zura Bio is more favorable than its rivals.

Profitability

This table compares Zura Bio and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-37.36%	-29.81%
Zura Bio Competitors	-2,185.76%	-161.46%	-40.62%

Insider & Institutional Ownership

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 22.1% of Zura Bio shares are owned by company insiders. Comparatively, 15.7% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Zura Bio beats its rivals on 11 of the 13 factors compared.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.